These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 10613656

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effects of recombinant human soluble thrombomodulin (rhs-TM) on clot-induced coagulation in human plasma.
    Mohri M, Suzuki M, Sugimoto E, Sata M, Yamamoto S, Maruyama I.
    Thromb Haemost; 1998 Dec; 80(6):925-9. PubMed ID: 9869162
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. In vitro anticoagulant properties of a minimum functional fragment of human thrombomodulin and in vivo demonstration of its benefit as an anticoagulant in extracorporeal circulation using a monkey model.
    Suzuki M, Mohri M, Yamamoto S.
    Thromb Haemost; 1998 Feb; 79(2):417-22. PubMed ID: 9493601
    [Abstract] [Full Text] [Related]

  • 6. Evidence that the protein C activation pathway amplifies the inhibition of thrombin generation by recombinant human thrombomodulin in plasma.
    Ohishi R, Watanabe N, Aritomi M, Gomi K, Kiyota T, Yamamoto S, Ishida T, Maruyama I.
    Thromb Haemost; 1993 Sep 01; 70(3):423-6. PubMed ID: 8259542
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. An antifibrinolytic effect associated with an anti-factor V antibody in a patient with severe thrombophilia.
    Colucci M, Simioni P, Piro D, Prandoni P, Pagnan A, Semeraro N.
    Haematologica; 2003 Dec 01; 88(12):1383-9. PubMed ID: 14687992
    [Abstract] [Full Text] [Related]

  • 10. The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma.
    Lindhout T, Blezer R, Hemker HC.
    Thromb Haemost; 1990 Nov 30; 64(3):464-8. PubMed ID: 2096492
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The technique of measuring thrombin generation with fluorogenic substrates: 3. The effects of sample dilution.
    De Smedt E, Wagenvoord R, Coen Hemker H.
    Thromb Haemost; 2009 Jan 30; 101(1):165-70. PubMed ID: 19132204
    [Abstract] [Full Text] [Related]

  • 16. The efficiency of anti-activated factor X and anti-activated factor II anticoagulants.
    Stief TW.
    Blood Coagul Fibrinolysis; 2007 Apr 30; 18(3):265-9. PubMed ID: 17413764
    [Abstract] [Full Text] [Related]

  • 17. Thrombomodulin in human plasma contributes to inhibit fibrinolysis through acceleration of thrombin-dependent activation of plasma procarboxypeptidase B.
    Hosaka Y, Takahashi Y, Ishii H.
    Thromb Haemost; 1998 Feb 30; 79(2):371-7. PubMed ID: 9493593
    [Abstract] [Full Text] [Related]

  • 18. The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT.
    Cimenti C, Koestenberger M, Leschnik B, Haidl H, Muntean W.
    Thromb Res; 2007 Feb 30; 119(3):361-7. PubMed ID: 16712904
    [Abstract] [Full Text] [Related]

  • 19. Differential effects of factor IIa inhibitors on the endogenous thrombin potential.
    Beilfuss A, Grandoch M, Wenzel F, Hohlfeld T, Schrör K, Weber AA.
    Ther Drug Monit; 2008 Dec 30; 30(6):740-3. PubMed ID: 18824953
    [Abstract] [Full Text] [Related]

  • 20. Enhancing protein C interaction with thrombin results in a clot-activated anticoagulant.
    Richardson MA, Gerlitz B, Grinnell BW.
    Nature; 1992 Nov 19; 360(6401):261-4. PubMed ID: 1436107
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.